IBD therapeutic developments and their application in daily clinical practice

This webcast will examine important recent developments in the field of IBD and the expanding treatment options. This includes an overview of targeting the IL-12/23 pathway in Crohn’s disease and the associated long-term data and real-world evidence. Furthermore, an update will be given on the current treatment options for ulcerative colitis, including key IL-12/23 inhibition data in patients with UC. The speakers will present patient cases to discuss the implications of these data in daily practice for the treatment of IBD. The audience worldwide will have the opportunity to connect with the faculty throughout the programme. We hope you can join us during this live, interactive session. If you are unable to attend the live broadcast, you will be able to watch the on-demand version once it is available. 

Learning Objectives 

After attending the meeting, attendees should be able to:

• Describe the long-term data and real world evidence (RWE) from Crohn’s disease (CD) and recent data from ulcerative colitis (UC) regarding therapies targeting the IL-12/23 pathway
• Identify patients who may be suitable for anti IL12/23 treatment based on recent data
• Apply these data into daily clinical practice  

 Faculty

• Jonas Halfvarson (Scientific Committee) 
• Marieke Pierik 
• Séverine Vermeire (Scientific Committee)